Hospital Nacional Zacamil
San Salvador, El Salvador
NCT Number: NCT07508592
This is a first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
The study will include patients undergoing procedures such as small bowel-small bowel and colorectal anastomoses. The SEGER device is intended to facilitate closure of enterotomies and support intracorporeal anastomosis during minimally invasive surgery.
The primary objective of the study is to assess the safety of the device and its performance during surgery. Secondary objectives include evaluation of technical success, intraoperative usability, and early postoperative outcomes.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
San Salvador, El Salvador
This is a prospective, single-arm, first-in-human feasibility study designed to evaluate the safety and performance of the SEGER device in patients undergoing elective laparoscopic gastrointestinal surgery requiring intracorporeal anastomosis.
The study will be conducted at a single clinical site in El Salvador. Eligible patients are adults undergoing elective laparoscopic procedures involving intracorporeal anastomosis, including but not limited to small bowel-small bowel (e.g., jejuno-jejunal) and colorectal anastomoses.
The SEGER device is intended to facilitate closure of enterotomies and support the creation of intracorporeal anastomoses during minimally invasive surgery. The device will be used intraoperatively according to the study protocol and the investigator's clinical judgment.
The primary objective of the study is to evaluate the safety of the device, including the incidence of device-related and procedure-related adverse events. Secondary objectives include assessment of device performance, technical success, intraoperative usability, and early postoperative outcomes.
Patients will be followed postoperatively according to the study protocol to assess clinical outcomes and recovery. Data collected will include intraoperative parameters, device performance metrics, and postoperative clinical outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The SEGER device is an investigational surgical device used during laparoscopic gastrointestinal procedures to facilitate intracorporeal closure of enterotomies and support small bowel anastomosis. The device is applied intraoperatively as part of the surgical workflow.
Time frame: Within 30 days post-surgery
Incidence of anastomotic leaks within 30 days post-surgery, assessed by clinical symptoms, imaging findings, or need for reoperation.
Time frame: Intraoperative
Proportion of procedures with successful deployment of the SEGER IDEA™ device without intraoperative complications.
Time frame: Within 30 days post-surgery
Incidence of postoperative complications including bleeding, infection, stricture formation, or device-related adverse events.
Time frame: Intraoperative
Time from device deployment to completion of enterotomy closure.
Time frame: Up to 30 days post-surgery
Number of days from surgery to hospital discharge.
Time frame: Intraoperative
Use of additional techniques such as reinforcement suturing or alternative closure methods.
Time frame: Within 30 days post-surgery
Time to return to normal diet, bowel function, and physical activity.
Seger Surgical Solutions
Industry
A Prospective Study on the Usability and Clinical Outcomes of the SEGER IDEA™ Device for Enterotomy Closure
Acronym: SEGER-FIH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00600496
Breast Cancer, Breast Diseases
Detroit, Michigan, United States
View Trial DetailsNCT03446157
Cancer of the Colon, Colon Cancer
Chapel Hill, North Carolina, United States
View Trial DetailsNCT04232176
Colon Cancer, Colon Neoplasms
Granada, Spain
View Trial DetailsNCT01424293
Colon Neoplasms, Colonic Diseases
Brooklyn, New York, United States
View Trial Details